



# Alectinib (Alecensa®)

Lungenkarzinom, nicht-kleinzellig (NSCLC) » ALK+ » ab  
Zweitlinientherapie

Empfehlungen der Fachgesellschaft zum Einsatz neuer Arzneimittel

## **Herausgeber**

DGHO Deutsche Gesellschaft für Hämatologie und  
Medizinische Onkologie e.V.  
Bauhofstr. 12  
10117 Berlin

Geschäftsführender Vorsitzender: Prof. Dr. med. Andreas Hochhaus

Telefon: +49 (0)30 27 87 60 89 - 0

[info@dgho.de](mailto:info@dgho.de)

[www.dgho.de](http://www.dgho.de)

## **Ansprechpartner**

Prof. Dr. med. Bernhard Wörmann  
Medizinischer Leiter

## **Quelle**

[www.onkopedia.com](http://www.onkopedia.com)

Die Empfehlungen der DGHO für die Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen entbinden die verantwortliche Ärztin / den verantwortlichen Arzt nicht davon, notwendige Diagnostik, Indikationen, Kontraindikationen und Dosierungen im Einzelfall zu überprüfen! Die DGHO übernimmt für Empfehlungen keine Gewähr.

# Inhaltsverzeichnis

<b>1 Alectinib, NSCLC, ALK+, second line .....</b>	<b>2</b>
--	----------


# Alectinib (Alecensa®)

**Dokument:** Fact Sheet

**Spezifizierung:** Lungenkarzinom, nicht-kleinzellig (NSCLC) » ALK+ » ab Zweitlinientherapie

**Stand:** Juli 2021

## 1 Alectinib, NSCLC, ALK+, second line

Alectinib, NSCLC, ALK+, second line																																																																											
	<b>Facts</b>	<b>Appraisal</b>	EU Approval 2017																																																																								
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Parameter</th> <th style="text-align: left;">Results<sup>14</sup></th> <th style="text-align: left;">HR<sup>15</sup></th> <th style="text-align: left;">p value</th> </tr> </thead> <tbody> <tr> <td>RR<sup>2</sup></td> <td>2.9 vs 37.5</td> <td></td> <td></td> </tr> <tr> <td>PFS<sup>3</sup></td> <td>1.4 vs 9.6</td> <td>0.15</td> <td>p &lt; 0.001</td> </tr> <tr> <td>OS<sup>5</sup></td> <td>n.r.<sup>18</sup> vs 12.6</td> <td></td> <td>n.s.<sup>16</sup></td> </tr> <tr> <td>SAE<sup>7</sup></td> <td>42.1 vs 27.1</td> <td></td> <td></td> </tr> </tbody> </table> <p>Remarks: 62.9% of patients in the control arm received Alectinib at a later stage (crossover/switching).</p>	Parameter	Results <sup>14</sup>	HR <sup>15</sup>	p value	RR <sup>2</sup>	2.9 vs 37.5			PFS <sup>3</sup>	1.4 vs 9.6	0.15	p < 0.001	OS <sup>5</sup>	n.r. <sup>18</sup> vs 12.6		n.s. <sup>16</sup>	SAE <sup>7</sup>	42.1 vs 27.1			<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Evidence (LoE)</th> <th>5</th> <th>4</th> <th>3b</th> <th>3a</th> <th>2c</th> <th>2b</th> <th>2a</th> <th>1b</th> <th>1a</th> </tr> </thead> <tbody> <tr> <td></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: black;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> </tr> </tbody> </table> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Clinical benefit (ESMO MCBS)</th> <th>1</th> <th>2</th> <th>3</th> <th>4</th> <th>5</th> </tr> </thead> <tbody> <tr> <td></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: yellow;"></td> <td style="background-color: #cccccc;"></td> </tr> </tbody> </table> <p> <span style="color: blue;">■</span> curative    <span style="color: yellow;">■</span> non-curative         </p>	Evidence (LoE)	5	4	3b	3a	2c	2b	2a	1b	1a											Clinical benefit (ESMO MCBS)	1	2	3	4	5							<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Additional benefit (G-BA)</th> <th>lower</th> <th>proven</th> <th>not quantifiable</th> <th>not minor</th> <th>considerable</th> <th>major</th> </tr> </thead> <tbody> <tr> <td>suitable for other systemic treatment<sup>29</sup></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: black;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> </tr> <tr> <td>not suitable for other systemic treatment<sup>30</sup></td> <td style="background-color: black;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> </tr> </tbody> </table>	Additional benefit (G-BA)	lower	proven	not quantifiable	not minor	considerable	major	suitable for other systemic treatment <sup>29</sup>							not suitable for other systemic treatment <sup>30</sup>						
Parameter	Results <sup>14</sup>	HR <sup>15</sup>	p value																																																																								
RR <sup>2</sup>	2.9 vs 37.5																																																																										
PFS <sup>3</sup>	1.4 vs 9.6	0.15	p < 0.001																																																																								
OS <sup>5</sup>	n.r. <sup>18</sup> vs 12.6		n.s. <sup>16</sup>																																																																								
SAE <sup>7</sup>	42.1 vs 27.1																																																																										
Evidence (LoE)	5	4	3b	3a	2c	2b	2a	1b	1a																																																																		
Clinical benefit (ESMO MCBS)	1	2	3	4	5																																																																						
Additional benefit (G-BA)	lower	proven	not quantifiable	not minor	considerable	major																																																																					
suitable for other systemic treatment <sup>29</sup>																																																																											
not suitable for other systemic treatment <sup>30</sup>																																																																											
<table border="1" style="width: 100%; border-collapse: collapse;"> <tbody> <tr> <td><b>Patients</b></td> <td>ALK+, after Crizotinib</td> </tr> <tr> <td><b>Trial</b></td> <td>ALUR, phase 3</td> </tr> <tr> <td><b>Randomisation</b></td> <td>1 : 1</td> </tr> <tr> <td><b>N<sup>1</sup></b></td> <td>107</td> </tr> <tr> <td><b>New Therapy</b></td> <td>Alectinib</td> </tr> <tr> <td><b>Control</b></td> <td>Docetaxel or Pemetrexed</td> </tr> <tr> <td><b>Publication</b></td> <td>DOI:10.1093/annonc/mdy121</td> </tr> </tbody> </table>	<b>Patients</b>	ALK+, after Crizotinib	<b>Trial</b>	ALUR, phase 3	<b>Randomisation</b>	1 : 1	<b>N<sup>1</sup></b>	107	<b>New Therapy</b>	Alectinib	<b>Control</b>	Docetaxel or Pemetrexed	<b>Publication</b>	DOI:10.1093/annonc/mdy121																																																													
<b>Patients</b>	ALK+, after Crizotinib																																																																										
<b>Trial</b>	ALUR, phase 3																																																																										
<b>Randomisation</b>	1 : 1																																																																										
<b>N<sup>1</sup></b>	107																																																																										
<b>New Therapy</b>	Alectinib																																																																										
<b>Control</b>	Docetaxel or Pemetrexed																																																																										
<b>Publication</b>	DOI:10.1093/annonc/mdy121																																																																										

Legende:

<sup>1</sup> N - number of patients

<sup>2</sup> RR - remission rate, in %

<sup>3</sup> PFS - progression-free survival in months

<sup>5</sup> OS - overall survival in months

<sup>7</sup> SAE - serious adverse events, CTCAE grade 3/4

<sup>14</sup> results for control, results for new therapy

<sup>15</sup> hazard ratio for new therapy

<sup>16</sup> n. s. not significant

<sup>18</sup> n. r. - median not reached

<sup>29</sup> Pemetrexed, Docetaxel or Ceritinib

<sup>30</sup> Pemetrexed, Docetaxel or Ceritinib